Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MRI (magnetic resonance imaging) imaging agent gains NCI (US National Cancer Institute) support:

This article was originally published in Clinica

Executive Summary

Targesome has received support from the US National Cancer Institute (NCI) to further its development of an MRI-based molecular imaging agent that can help detect cancer and metastatic disease. The Palo Alto, California company is investigating the use of its proprietary nanoparticles that target new blood vessel formation, a process essential for tumour growth and metastases. The technique involves the use of a human monoclonal antibody which is attached to Targesome's injectable nanoparticles labelled with gadolinium ions and which binds to a specific endothelial marker.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT070217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel